ASH Clinical News ACN_4.6_Full_Issue_web | Page 71

FEATURE against Canada Drugs and its affiliates, charging the company with smuggling, money laundering, and conspiracy. 15 The company’s website says it offers low-priced medicines from Canada, the U.K., Austra- lia, and New Zealand; the company was accused of falsifying customs declarations on the value of drugs, improper storage of the drugs, and sales of counterfeit medi- cine. In all, the company and its affiliates were charged with crimes related to the sale of $78 million in mislabeled or counterfeit prescription drugs. The company again was fined for illegal importation in April 2018 for importing counterfeit cancer drugs and other unap- proved pharmaceuticals into the U.S. 16 A federal judge in Montana approved federal prosecutors’ recommended sentences, totaling $34 million in fines and five years’ probation for Canada Drugs. The online pharmacy also will permanently cease the sale of all unapproved, misbranded, and counterfeit drugs and will surrender all the domain names for the websites through which it sells drugs. “There is concern that there have been fake cancer medications distributed, not only to pharmacies but to doctors’ offices and hospitals throughout the U.S.,” said Kenneth L. McCall, PharmD, associate professor in the College of Pharmacy at University of New England in Portland, Maine. “People are worried that these medications do not contain ingredients that they are labeled to contain and may contain contaminants.” State Solutions To try to circumvent what they perceive as inaction at the federal level, several states have recently put forth legislation that would allow for the importation of prescription drugs from Canada.